ClinicalTrials.gg
Status unknownNCT04586803Updated Oct 14, 2020

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers

A Phase 1 interventional study of SHR4640 in Primary Gout and Hyperuricemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-14.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing ruzinurad in Hyperuricemia — 1 open to participants now, 1 under way, none of them phase 3. ruzinurad · Hyperuricemia.

Planned enrollment
8th of 11
24 · median 34
Started
2020
the only one that year
Phase 1
8 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
10 of 11
Jiangsu HengRui Medicine Co., Ltd.

Among the 11 studies testing ruzinurad in Hyperuricemia, this one is the 8th largest by planned enrollment, is the only one that started in 2020, is one of 8 in phase 1, and was the 6th registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

1 of the 11 studies testing ruzinurad in Hyperuricemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About ruzinurad

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ruzinurad in Hyperuricemia, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the relative bioavailability of three different prescription processes of SHR4640 tablets in healthy volunteers. The secondary objective of the study is to observe the safety of SHR4640 tablets in healthy subjects.

Read the detailed description

Study Type: Interventional Enrollment: Number of Subjects: 24 Type: Anticipated

Allocation : Yes Intervention Model : Single center, randomized, open Intervention Model Description: 3 cycles, 6 sequences Masking: No Masking

Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

03

Conditions studied

  • Primary Gout
  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Voluntarily sign the form before the start of the activities related to this trial, and be able to understand the procedures and methods of this trial, and be willing to strictly abide by the clinical trial plan to complete this trial; 2) Aged between 18 and 45 years old (including both ends, whichever is the time of signing the informed consent form), male; 3) Body weight ≥ 50 kg, and (BMI): 19-26 kg/m2 (both ends included).

Exclusion criteria

Exclusion Criteria:

  • Subjects will not be allowed to enter this study if they meet any of the following criteria:

    1. General situation:
    2. Have a fertility plan within 3 months after screening to the last medication, or refuse to use medically approved methods;
    3. Drug abusers or drug urine screening positive;
    4. Smokers (average daily smoking 5 or more) or urine Nicotin positive.
    5. The average daily alcohol intake during the first month was more than 25 g (for example, 750 mL beer, 250 mL wine or 50 mL low spirits);
    6. Anyone who had eaten grapefruit or fruit juice products within 2 days before administration, any food or drink containing caffeine (such as coffee, tea, chocolate, cola or other caffeinated carbonated drinks, etc.) and foods or drinks rich in purine food or alcohol.
    7. The researchers judged that the subjects had medical conditions that affected the absorption, distribution, metabolism and excretion of drugs or reduced compliance.
    1. Laboratory tests showed the following conditions:
    2. Those with sUA > 420 µmol / L during the screening period, or those with a previous history of hyperuricemia and / or gout;
    3. Those with estimated (eGFR) \< 90 during the screening period;
    4. Those with urolithiasis indicated or suspected by B ultrasound during the screening period;
    5. Those who were positive for surface antigen (HBsAg), anti- virus (HCV) antibody, (HIV) antibody or syphilis antibody within one month or during the screening period.
    1. There is any history of any of the following or concomitant diseases:
    2. Any clinical history of serious illness or disease or condition that the researchers believe may affect the results of the trial, including, but not limited to, a history of circulatory, endocrine, nervous, digestive, urinary or hematological, immune, mental and metabolic diseases.
    3. People with allergies, including those who are explicitly allergic to research drugs or any ingredient in research drugs, are allergic to any food ingredient or have special requirements for diet, and are unable to follow a uniform diet;
    4. Screening those who have undergone any operation within the first 3 months, or who have not recovered after the operation, or who may have a plan for operation or hospitalization during the trial;
    5. Those who donated blood (or lost blood) within the first 3 months and donated blood (or lost blood) more than 400 mL, or received blood transfusion.
    1. Use any of the following drugs or participate in clinical trials:
    2. Screen people who have participated in clinical trials of any drug or medical device within the previous 3 months;
    3. Take any prescription drug, over-the-counter medicine, Chinese herbal medicine or dietary supplement within 2 weeks before the screening period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    A

    Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

    Drug: SHR4640

  • Experimental
    B

    Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

    Drug: SHR4640

  • Experimental
    C

    Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

    Drug: SHR4640

  • Experimental
    D

    Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

    Drug: SHR4640

  • Experimental
    E

    Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

    Drug: SHR4640

  • Experimental
    F

    Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

    Drug: SHR4640

Interventions

  • Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.

06

What researchers measure

Primary outcomes

  1. Cmax

    Peak plasma concentration

    Time frame: Day1 to Day25

  2. AUC0-t

    Area under the curve from the time of dosing. Dosing time to the last measurable (positive) concentration.

    Time frame: Day1 to Day25

  3. AUC0-inf(if available)

    Area under the curve from time 0 to infinity

    Time frame: Day1 to Day25

Secondary outcomes

  1. Tmax

    Time of maximum observed concentration

    Time frame: Day1 to Day25

  2. t1/2

    Half time

    Time frame: Day1 to Day25

  3. CL/F

    apparent clearance

    Time frame: Day1 to Day25

  4. Vz/F

    apparent volume of distribution

    Time frame: Day1 to Day25

  5. PD

    concentration of serum urine acid

    Time frame: Day1 to Day25

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2020; primary completion for Nov 2020, 1 month later.

Of 29 industry-sponsored phase 1 interventional studies under Hyperuricemia, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's planned 1 month is below that.

Counting every sponsor, half of 31 studies reached it within 6 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2020
First posted
Oct 14, 2020
StartEst.
Oct 2020
Primary completionEst.
Nov 2020
CompletionEst.
Dec 2020
Last update
Oct 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04586803
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Oct 2020 (estimated)
Primary completion
Nov 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Oct 14, 2020

Study contacts

Sheng Zhong, Master
Contact
zhongsheng@hrglobe.cn
13564101315 ext. +86
Yuxiong Gao, PhD
Contact
gaoyuxiong@hrglobe.cn
19821262236 ext. +86
Zourong Ruan, PhD
principal investigator · The Second Affiliated Hospital of Medical College of Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion